Welcome to our dedicated page for American Vanguard SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Vanguard Corporation's SEC filings document the formal disclosures of a NYSE-listed specialty agriculture products company and its AMVAC Chemical Corporation operating subsidiary. Recent Form 8-K reports cover operating results, earnings-call materials, Regulation FD disclosures and material credit arrangements, including term-loan and revolving-credit amendments tied to the company's capital structure and working-capital needs.
Proxy and annual-meeting filings address board elections, director composition, auditor ratification, executive compensation and shareholder voting matters. The filings also identify the company's common stock, par value, exchange listing and governance actions related to board size and committee-level oversight.
AMERICAN VANGUARD CORP director Rubin J. McDougal has filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director but shows no reported transactions, meaning it simply establishes his status as an insider without disclosing any recent trades.
American Vanguard Corp’s Chief Commercial Officer, Michael Joseph DiPaola, received an incentive stock option grant. The award covers 20,000 options to buy common stock at an exercise price of $2.51 per share.
The options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary, June 4, 2036, if not exercised. This is a compensation-related equity grant rather than an open-market share purchase or sale.
AMERICAN VANGUARD CORP director Patrick E. Gottschalk received a grant of 31,872 deferred stock units. These DSUs were awarded as part of the compensation program for non-management directors in connection with the 2026 annual stockholders' meeting, at no cash cost per unit. Following the award, Gottschalk holds 223,577 shares or units of common stock-related interests directly. Each DSU converts into one share of common stock upon settlement, which occurs when his board service ends, upon a change of control, or upon his death.
American Vanguard Corp senior vice president Jared Straley received a grant of options to buy 20,000 shares of common stock. The incentive stock options have an exercise price of $2.51 per share, vest in full on the third anniversary of the June 4, 2026 grant, and expire on June 4, 2036.
American Vanguard Corp CHRO Shirin Khosravi received a grant of options to buy 20,000 shares of common stock. These incentive stock options have an exercise price of $2.51 per share and relate to 20,000 underlying common shares.
The options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary, June 4, 2036. Following this award, Khosravi holds options to acquire 20,000 shares directly, reflecting a compensation-related equity grant rather than an open-market purchase or sale.
AMERICAN VANGUARD CORP senior vice president of manufacturing Gilliam Nolteanous received a grant of stock options. The award covers 20,000 options to buy common stock at an exercise price of $2.51 per share.
These incentive stock options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary, June 4, 2036. Following this grant, Nolteanous holds 20,000 options directly, reflecting compensation rather than an open-market share purchase.
AMERICAN VANGUARD CORP officer Timothy J. Donnelly received a grant of options covering 20,000 shares of common stock. The options have an exercise price of $2.51 per share and were reported as a direct holding.
These incentive stock options vest in full on the third anniversary of the grant date and expire on the tenth anniversary of the grant date. The grant is categorized as a compensation-related acquisition, with no open-market buying or selling of common shares reported in this filing.
Macicek Steven D reported acquisition or exercise transactions in this Form 4 filing.
American Vanguard Corp director Steven D. Macicek reported an equity award of 31,872 deferred stock units (DSUs) of common stock. The units were granted at no cash cost as part of the company’s compensation program for non‑management directors in connection with the 2026 annual stockholders’ meeting.
Each DSU represents the right to receive one share of common stock upon settlement, which occurs when Macicek’s board service ends, upon a change of control, or upon his death. After this grant, he directly holds 80,711 shares or share-equivalent units. DSUs are nontransferable during service and carry neither voting nor dividend rights until they settle.
American Vanguard Corp director Mark R. Bassett received a grant of 31,872 deferred stock units (DSUs) of common stock as part of the company’s 2026 non-management director compensation program. Following this award, he directly holds 89,919 shares or DSUs in total. Each DSU converts into one common share upon settlement when his board service ends, upon a change of control, or upon his death, and carries no voting or dividend rights while outstanding.
Angelini Marisol reported acquisition or exercise transactions in this Form 4 filing.
American Vanguard Corp director Marisol Angelini received a stock grant. She was awarded 31,872 shares of Common Stock at no cash cost as part of the Company's compensation program for non-management directors in connection with the 2026 annual stockholders' meeting. Following this award, she directly holds 68,762 shares of American Vanguard common stock.